Obesity induced in mice by high-fat feeding activates the protein kinase Cdk5 (cyclin-dependent kinase 5) in adipose tissues. This results in phosphorylation of the nuclear receptor PPARc (peroxisome proliferator-activated receptor c), a dominant regulator of adipogenesis and fat cell gene expression, at serine 273. This modification of PPARc does not alter its adipogenic capacity, but leads to dysregulation of a large number of genes whose expression is altered in obesity, including a reduction in the expression of the insulin-sensitizing adipokine, adiponectin. The phosphorylation of PPARc by Cdk5 is blocked by anti-diabetic PPARc ligands, such as rosiglitazone and MRL24. This inhibition works both in vivo and in vitro, and is completely independent of classical receptor transcriptional agonism. Similarly, inhibition of PPARc phosphorylation in obese patients by rosiglitazone is very tightly associated with the anti-diabetic effects of this drug. All these findings strongly suggest that Cdk5-mediated phosphorylation of PPARc may be involved in the pathogenesis of insulin-resistance, and present an opportunity for development of an improved generation of anti-diabetic drugs through PPARc.
Adipose tissue is at the centre of metabolic syndrome. Excessive body fat defines obesity and leads to insulin resistance, dyslipidaemia, type 2 diabetes, certain cancers and cardiovascular disease. Understanding the molecular pathways that link adipose tissue biology to this array of pathologies is of paramount scientific and medical importance. Adipose cells and tissues secrete a variety of cytokines and cytokinelike molecules, called adipokines, which have positive or negative effects on insulin sensitivity, circulating lipid levels and appetite 1 . In obesity, TNF-a, IL-1 and resistin are secreted from adipose tissues and suppress insulin action on peripheral tissues [2] [3] [4] . Conversely, adipose tissues from lean individuals secrete higher levels of adiponectin, a circulating protein that has insulin-sensitizing effects on liver and other tissues [5] [6] [7] .
Action of PPARc
The nuclear receptor PPARc can be thought of as a 'master' gene of fat cell biology and differentiation, being both necessary and sufficient to drive conversion of fibroblastic precursors into fat cells [8] [9] [10] .
Other key transcription factors, including C/EBPs and EBF proteins, regulate the expression of PPARc 11, 12 . Thiazolidinedione drugs (such as rosiglitazone and pioglitazone) are synthetic ligands functioning as strong agonists on PPARc, and are potent insulin-sensitizing agents 13 . Although the structural basis for the insulin sensitizing effects of these drugs is unclear, their actions result in decreased expression of insulin-resistance-inducing adipokines including TNF-a, IL-1 and resistin, and increased production of the insulinsensitizing hormone, adiponectin 14, 15 . Unfortunately, PPARc agonists can have long-term adverse effects on the health of certain patients, such as increased body weight, fluid retention and increased risk of heart failure 16 .
Several important aspects of PPARc action remain confusing and unresolved. First, there is no general deficiency in PPARc function in obesity or insulin-resistant states. Hence, it is not clear why synthetic activation of a receptor should give such dramatic anti-diabetic effects. Second, although anti-diabetic potency of the PPARc ligand drugs correlates very well with their binding affinities 17 , some ligands with full agonist action, like rosiglitazone, have powerful insulinsensitizing actions, while other compounds with poor agonist activities, such as the benzyl indole MRL24, retain very good anti-diabetic effects 18 .
We show here that phosphorylation of PPARc by Cdk5 neither activates nor suppresses general receptor transcriptional activity, but changes the expression of specific genes, such as adiponectin. Cdk5mediated phosphorylation of PPARc is linked to obesity induced in mice by high-fat feeding. Several anti-diabetic PPARc ligands, with or without classical agonist properties, directly inhibit this action of Cdk5 on PPARc, and restore a more normal, non-diabetic pattern of gene expression. In addition, inhibition of this PPARc phosphorylation in humans by rosiglitazone is closely associated with its antidiabetic effects. This unusual pharmacology suggests a surprising model for a Cdk5-PPARc link in the pathogenesis of obesity/diabetes and for the therapeutic action of PPARc ligands in these disorders.
Cdk5 phosphorylates PPARc at Ser 273 in vitro and in vivo
Pro-inflammatory cytokines are secreted from both fat cells and immune cells residing in adipose tissue, particularly when animals or humans become obese 2 . We noted with interest that the primary amino acid sequence of PPARc contained a consensus site for phosphorylation by Cdk5 at Ser 273 of PPARc2 ( Supplementary Fig. 1a ). This protein kinase is not regulated by cyclins, but is instead activated by p35/25, which are targets of numerous cytokines and pro-inflammatory signals 19 . When murine PPARc was incubated in vitro with Cdk5 and its cofactor p35 ( Fig. 1a ), the nuclear receptor was phosphorylated as efficiently as histone H1, a known substrate of the Cdk5/p35 complex. Mutation of Ser 273 to alanine completely blocked phosphorylation by Cdk5, indicating that there were no other Cdk5 sites in PPARc detected by an antibody that recognizes phosphorylated Cdk5 consensus sites ( Fig. 1a ). Other members of the Cdk protein family did not phosphorylate PPARc ( Supplementary  Fig. 1b ). Cdk5 also phosphorylated PPARc at Ser 273 in cells, as shown by co-transfection of the kinase with wild-type (WT) and mutant PPARc ( Supplementary Fig. 1c ). Finally, Cdk5 did not modify murine PPARa or PPARd ( Supplementary Fig. 1d ).
Obesity is characterized by elevated circulating and local levels of pro-inflammatory cytokines and free fatty acids, and Cdk5 is activated by various cytokines 19, 20 . Figure 1b illustrates that treatment of 3T3-L1 adipocytes with TNF-a caused phosphorylation at Ser 273 of PPARc. Furthermore, the phosphorylation of PPARc at Ser 273 occurred on treatment of fat cells with IL-6 or free fatty acids (FFAs) ( Supplementary Fig. 2a and b ). These modifications were greatly suppressed by a short hairpin RNA (shRNA) directed against murine Cdk5 ( Fig. 1c and Supplementary Fig. 2c ) or roscovitine, a selective Cdk5 inhibitor ( Supplementary Fig. 2d ). Although cytokines and FFA may affect other phosphorylation sites within PPARc, these results strongly suggest that the phosphorylation at Ser 273 of PPARc is occurring specifically through Cdk5.
We next asked how the Ser-273 phosphorylation of PPARc altered the ability of this receptor to affect adipogenesis and gene expression within differentiated adipocytes. Wild-type and S273A mutant alleles of PPARc had the same transcriptional activity on a PPAR-response element ( Supplementary Fig. 3 ) when expressed in fibroblasts previously engineered to completely lack this receptor ( Fig. 1d , Supplementary Fig. 4a ) 21 . These initial experiments took advantage of the considerable serum-induced basal level of Cdk5 activity in cultured cells 22 . Although treatment of cells with cytokines and FFAs induced a more robust activation of Cdk5, these treatments also lead to de-differentiation of adipocytes 23 . The mutant and WT PPARc alleles both drove PPARc-mediated adipogenesis with equal efficiency (Fig. 1e ). Although most classical adipocyte-selective genes, like aP2 and C/EBPa, were expressed to equal levels, certain transcripts-including the key fatty acid transporter cd36, and the adipokines adiponectin, adipsin and leptin-were sensitive to mutation of the Cdk5 site in PPARc ( Fig. 1e ). Mutation of the Cdk5 site also increased the secretion of adiponectin into the culture medium ( Supplementary Fig. 4b ). To understand how regulation of Ser 273 affects expression of adiponectin and other specific genes, we compared the chromatin association of phosphorylated and non-phosphorylated PPARc ( Supplementary Fig. 5 ). There were no differences in DNA binding by the phosphorylation of PPARc, suggesting that other factors, such as co-regulator recruitment to PPARc, may be differentially regulated in a phosphorylation-dependent manner. We next compared the ability of mutant and WT PPARc alleles to alter fat cell gene expression in vivo. Adiponectin and adipsin were markedly dysregulated, being elevated in transplanted fat pads expressing mutant versus WT PPARc (Fig. 1f ). Although both cd36 and leptin were expressed at slightly higher levels in cells expressing mutant receptor, this did not reach statistical significance.
It is notable that adiponectin and adipsin are inappropriately regulated in obesity 14, 15 . This led us to ask whether Cdk5 modification of PPARc is activated in adipose tissues of obese mice. Adipose tissues were harvested at several time points from mice placed on either a standard chow or a high-fat/high-sugar diet (in which 60% of the calorific value was derived from fat). As shown in Supplementary Table 1, overt hyperinsulinaemia was apparent at 13 weeks. There were detectable basal levels of Ser 273 phosphorylation of PPARc in chow fed animals, with no increase in this modification after 3 weeks on the high-fat diet ( Fig. 2a, Supplementary Fig. 6a ). Highfat feeding for 7 weeks led to increased phosphorylation of PPARc FFAs  TNF-α  IL-6  IL-1β  NT  FFAs  TNF-α  IL-6  IL-1β Cdk5 shRNA
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Leptin Leptin Relative gene expression compared to chow-fed controls, with the difference becoming more pronounced after 13 weeks. Similarly, there was no phosphorylation of Cdk5 after 3 weeks of high-fat feeding; however, activated Cdk5 was easily observed after 7 and 13 weeks of the high-fat diet ( Supplementary Fig. 6c ) along with increased levels of the cleaved p25 protein, the more stable form of the activating subunit for Cdk5 (ref. 19) . We also compared the Cdk5-mediated modification of PPARc in two different white fat depots: inguinal fat, a type of subcutaneous fat, and epididymal fat, a visceral depot 24 . Figure 2b and Supplementary Fig. 6b and d illustrate that the increase in phosphorylation by Cdk5 occurred in both white fat depots, with greater intensity in the epididymal depot.
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Anti-diabetic PPARc ligands block phosphorylation of PPARc
Anti-diabetic drugs of the thiazolidinedione (TZD) class, such as rosiglitazone, are agonist ligands for PPARc, improving insulin sensitivity in both mice and humans 10 . To investigate whether anti-diabetic PPARc ligands alter Cdk5-mediated phosphorylation of this receptor, we treated fat cells expressing WT PPARc with TNF-a, rosiglitazone, or a combination of these two agents. Figure 3a shows that rosiglitazone inhibited Ser 273 phosphorylation at approximately 1 mM, similar to the dose required for other PPARc-mediated activities in adipose cells 13 . GW9662, a PPARc antagonist 25 , completely blocked this effect of rosiglitazone. We also examined the effect of these compounds on the Cdk5-mediated phosphorylation of a naturally occurring mutant form of PPARc (Q286P) that no longer directly binds known ligands 26 . Rosiglitazone could not interfere with Cdk5 phosphorylation in this case, implying that direct binding of the ligand was required for inhibition. To address whether ligands work directly to inhibit Cdk5-mediated phosphorylation, we mixed purified PPARc, Cdk5/p35 and rosiglitazone under conditions to achieve modification in vitro. Rosiglitazone blocked Ser 273-phosphorylation in vitro, with a half maximally effective dose of about 30 nM (Fig. 3b ), near the K d of this compound for PPARc binding 13 . Importantly, this inhibition is not caused by a general inhibition of Cdk5 activity, as incubation with rosiglitazone did not inhibit the ability of Cdk5 to phosphorylate Rb (Fig. 3c ). MRL24 is a non-TZD compound with high affinity for PPARc, with excellent anti-diabetic activity in mice 18 , but poor agonist properties towards PPARc in transcription and adipogenesis assays. As reported previously 18 and shown in Fig. 3d , MRL24 showed weak transcriptional activity compared to rosiglitazone. On the other hand, MRL24 was very effective at blocking Cdk5-mediated phosphorylation of PPARc (Fig. 3b ); 30 nM of MRL24 inhibited the modification of PPARc as effectively as 300 nM of rosiglitazone, both in vitro and in cells ( Fig. 3b, Supplementary Fig. 7a and b ). We also examined the ability of several other published PPARc ligands that have been shown to have poor agonist properties, but strong antidiabetic activities in vivo [27] [28] [29] . As shown in Supplementary Fig. 8 , Mbx-102, BVT.13 and nTZDpa were all effective at inhibiting the Cdk5-mediated phosphorylation of PPARc.
To systematically compare changes in gene expression caused by both the Ser 273 mutation in PPARc and specific PPARc ligands, we performed Affymetrix analyses of gene expression with RNA from cells expressing either WT or mutant PPARc, plus WT cells treated with rosiglitazone or MRL24. As shown in Fig. 3e , unbiased clustering of these data resulted in several notable clusters of expression. The overlap in global regulation of gene expression between the mutant form of PPARc and the PPARc ligands is highly significant (P , 0.005 for each drug versus mutation). Genes exhibiting differential expression between WT and mutant PPARc segregated into four major groups. One group, labelled 'a', were genes whose expression was decreased by Ser 273 mutation. This same group of genes was also suppressed by both rosiglitazone and MRL24, though neither ligand functioned as dramatically as did the non-phosphorylatable mutant of PPARc. This is understandable, as it is unlikely that ligand treatment caused complete dephosphorylation of PPARc comparable to the mutant protein. The very small cluster labelled 'b' contained Ahnak nucleoprotein and proteolipid protein (plp) 1, which are critical for myelination 30, 31 , and sorting nexin 5 (Snx5), which is important for vesicle trafficking 32 . A larger cluster, labelled 'c', represented genes decreased by Cdk5-mediated phosphorylation of PPARc. Several of the genes known to be dysregulated in obesity, including adiponectin 
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Adiponectin Adipsin Relative gene expression ARTICLES and adipsin, were present in this cluster. Rosiglitazone increased essentially all of these genes, but Fig. 3e indicates that this occurred as part of a very large gene set increased by rosiglitzone action. Indeed, genes induced most dramatically by rosiglitazone (labelled 'd') did not correspond to the Cdk5 mutation-induced gene set and were largely the classic genes of adipogenesis, like aP2 and lipoprotein lipase (Lpl).
In sharp contrast, the gene cluster strongly increased by MRL24 was much smaller than that induced by rosiglitazone, and corresponded remarkably well to the gene set induced by the mutation in the Cdk5 site of PPARc. Taken together, the data presented in Figs 1-3 suggest that Cdk5 modification of PPARc could be a major source of gene dysregulation and pathology of adipose tissues in obesity. To directly address this, we created refined gene sets regulated by the Cdk5 modification of PPARc, using the concept of principal component analysis of gene expression data ( Supplementary Fig. 9 ). Figure 3f shows that the great majority of these genes had dysregulated expression in an obesity-dependent manner. In total, of the 17 genes most significantly reduced by Cdk5 phosphorylation of PPARc, at least 12 were also decreased in obese mice. Interestingly, most of these genes were more significantly affected in epididymal fat tissue compared to the inguinal depot ( Supplementary Fig. 10 ), consistent with differential phosphorylation of PPARc in the two depots ( Fig. 2b ). In addition, shRNA-mediated knock-down of Cdk5 in cells resulted in marked dysregulation of the gene sets, particularly adiponectin and adipsin ( Supplementary Fig. 11 ), further confirming that Cdk5-mediated phosphorylation of PPARc plays a significant role in the regulation of specific fat cell genes.
To develop a structural understanding of how PPARc ligands affect Cdk5-mediated phosphorylation of PPARc, we turned to hydrogen/deuterium exchange (HDX) linked to mass spectrometry 33 . As shown in Fig. 4a , rosiglitazone, but not MRL24, significantly reduced H/D exchange in helix 12 (H12), which contains the ligand-binding domain comprising part of the AF-2 surface of the receptor responsible for classical agonism 34, 35 . On the other hand, MRL24 had a more marked impact on H/D exchange kinetics across H3 (amino acids 309-315), the b-sheet at 369-379, and the Cdk5 site itself at Ser 273 in PPARc. Rosiglitazone also affected the exchange across H3 and the b-sheet region, but did not significantly alter the H/D exchange across Ser 273. When these HDX data are mapped onto the known co-crystal structures of PPARc with each of these ligands bound, it is clear that MRL24 reduced the dynamic nature of these regions to a greater extent than rosiglitazone (Fig. 4b) . It is likely that the ligand-induced reduction in the dynamic nature of H3, the b-sheet and the Cdk5 site 'freezes' this region in a configuration less favourable to Cdk5 phosphorylation. As Cdk5 phosphorylation of PPARc does not affect chromatin occupancy of this receptor ( Supplementary Fig. 2) , we examined the possibility that the region near the Cdk5 site might be an important location for ligand-gated coregulator interactions. As shown in Supplementary Fig. 12 , HDX data show that a model coactivator, SRC3, interacts with a PPARc region far from helix 12, near Ser 273, when MRL24 is bound. Thus, specific coregulator modulation of PPARc by modifications at Ser 273 is highly plausible.
PPARc phosphorylation correlates with insulin sensitivity
Next, we asked whether the PPARc ligands alter Cdk5-mediated phosphorylation of PPARc in vivo. As shown in Fig. 5a and Supplementary Fig. 13 , treatment with either rosiglitazone or MRL24 at 10 mg kg 21 for 7 days dramatically improved glucose tolerance of high-fat fed mice and reduced fasting insulin levels without changing body weight. Importantly, both of these compounds reduced Cdk5-mediated phosphorylation of PPARc in the adipose tissue of every mouse treated (Fig. 5b) . These drugs did not affect the status of another known phosphorylation site, Ser 112 (Supplementary Fig. 14) . Furthermore, 12 of the 17 genes most significantly controlled by Cdk5 action on PPARc (as described above)
were altered by the action of one or both drugs (Fig. 5c ). These data demonstrate that anti-diabetic PPARc ligands inhibit Cdk5 phosphorylation of PPARc in vivo and reverse changes in gene expression linked to this modification. Consistent with these results, treatment with roscovitine significantly suppressed Cdk5-mediated phosphorylation and most of the gene set regulated by the phosphorylation of PPARc ( Supplementary Fig. 15 ). However, we cannot exclude the possibility that weight loss in the treatment group may be influencing changes in phosphorylation and gene expression.
Finally, we investigated whether humans undergoing therapy with a PPARc ligand showed decreased phosphorylation of PPARc at the Cdk5 site in adipose tissue, and how this correlated with improvements in systemic insulin sensitivity. Newly diagnosed patients need to control diabetes either with drugs or by means of diet, exercise and weight loss. As phosphorylation of PPARc is induced by obesity, weight loss may affect it too. Therefore, each patient treated with rosiglitazone served as their own 'control', before and after therapy. As shown in Fig. 5d , Ser 273 phosphorylation of PPARc was generally decreased in subcutaneous fat biopsies from patients following rosiglitazone treatment. However, one patient displayed increased phosphorylation and two patients showed only a modest decrease. Notably, patients who had little or no reduction in PPARc phosphorylation also displayed little improvement in clinical parameters such as fasting insulin and fasting glucose with rosiglitazone treatment (Supplementary Tables 2  and 3 ). To investigate the relationship of these effects to changes in insulin sensitivity, we compared the final, euglycaemic, hyperinsulinaemic clamped glucose infusion rate with the relative change in PPARc phosphorylation for each patient. As shown in Fig. 5e , there was a powerful, negative correlation (r 5 20.92 and P 5 0.001) H12  20  35  60  12  10  8  6  4  2  0   50  40  30  20  10  0   30  25  20  15  10  5 between changes in glucose infusion rate and changes in PPARc phosphorylation. Thus, in this patient cohort, improvement of insulin sensitivity using rosiglitazone was tightly coupled to decreased phosphorylation of PPARc at the Cdk5 site.
Discussion
The data presented here suggest a unified framework for understanding the relationship between fat cell dysfunction in obesity and antidiabetic therapies through PPARc ( Supplementary Fig. 16 ). High-fat diets in vivo activate the protein kinase Cdk5. Cdk5-mediated phosphorylation of PPARc at Ser 273 dysregulated expression of a subset of genes; these included a number of key metabolic regulators, including adipsin, the first fat cell-selective gene whose expression is altered in obesity 36 and adiponectin, a central regulator of insulin sensitivity in vivo. Ser 273 phosphorylation did not alter the chromatin occupancy of PPARc, suggesting that other mechanisms, such as differential recruitment of co-regulators, may cause these differences in target gene expression. Anti-diabetic PPARc ligands inhibited Ser 273 phosphorylation and reversed associated changes in gene expression. Crucially, inhibition of Cdk5-mediated phosphorylation of PPARc by ligands altered the conformation/dynamic nature of the protein, such that Ser 273 was no longer modified by the protein kinase. In fact, a PPARc ligand with minimal agonist activity, such as MRL24, did this as well or better than a full agonist, such as rosiglitazone. Given that both have potent anti-diabetic activities; it is likely that a substantial portion of the therapeutic benefits of PPARc ligands in metabolic disease is through inhibition of Cdk5mediated phosphorylation. The studies presented in Fig. 5d and e also indicate that this specific phosphorylation was closely coupled to the therapeutic effects of rosiglitazone in humans. It is worth noting that the therapeutic doses used in animals did not lead to a complete inhibition of the Cdk5 phosphorylation of PPARc, so more robust therapy might be obtained with other, more narrowly targeted ligands.
On the basis of these results, the role of agonism in the actions of PPARc ligand drugs is quite unclear. It is possible that a small degree of agonism further enhances the beneficial effects of blocking Cdk5mediated phosphorylation of PPARc. On the other hand, it seems likely that at least some of the problematic side-effects of these drugs, including weight gain and fluid retention 16 , may occur through classical agonist actions. This can be better assessed as ligands with various degrees of agonism are evaluated in both preclinical models and human subjects. More broadly, the ability of 'partial agonists' to alter protein phosphorylation may be true for other members of the nuclear receptor family, possibly allowing for identification of new drugs.
How is Cdk5 activated in adipose tissues of obese mice? Both cytokines and fatty acids are elevated in adipose tissues in most obese states, and both may contribute to Cdk5 activation in the experiments preformed here. Cytokines and other stimulators of Cdk5 typically work via cleavage of the Cdk5 partner p35 into a more active and more stable p25 subunit 19 . Although the extracellular stimulator that functions on fat cells as a consequence of high-fat feeding is not established, it is clear from Supplementary Fig. 6 that the activation of Cdk5 in obesity is accompanied by enhanced formation of p25. Whether high-fat feeding and obesity lead to activation of Cdk5 in other non-adipose tissues is a very important question, as the negative effects of obesity extend far beyond the metabolic syndrome to cancer and neurodegeneration 37, 38 . Neurodegeneration has been associated with the abnormal activation of Cdk5 in the CNS 39 , so further studies are required to determine if Cdk5 is activated in the brain and other tissues in obesity.
METHODS SUMMARY
Cell culture. PPARc-null mouse embryonic fibroblasts (MEFs) 21 were cultured in Dulbecco's modified Eagle's medium and 10% fetal bovine serum. FLAG-PPARc and FLAG-PPARc S273A were subcloned into pMSCV-puro retrovial vector (Stratagene). Following infection of the cells with retrovirus, cells expressing ectopic protein were selected by incubation with 2 mg ml 21 puromycin. Adipocyte differentiation in 3T3-L1 or MEFs was induced by treating cells with 1 mM dexamethasone, 0.5 mM isobutylmethylxanthine, and 850 nM insulin for 48 h and cells were switched to the maintenance medium containing 850 nM insulin. In vitro kinase assay. Immuno-purified WT or S273A mutant of PPARc was incubated with active Cdk kinases in kinase assay buffer containing ATP for 15 min at 30 uC. Positive controls, either purified histone H1 (Millipore) or Rb (Cell Signaling Technology) were used. PPARc ligands were pre-incubated with substrates for 30 min prior to the assay. Gene expression analysis. Total RNA was isolated from cells or tissues using Trizol reagents (Invitrogen). The RNA was reverse-transcribed using ABI reverse transcription kit. Quantitative PCR reactions were performed with SYBR green fluorescent dye using an ABI 9300 PCR machine. Relative mRNA expression was determined by the DD-Ct method using TATA-binding protein (TBP) levels. Animals. All animal experiments were performed according to procedures approved by Beth Israel Deaconess Medical Center's Institutional Animal Care and Use Committee. 4 to 5 week-old male C57BL/6J mice were obtained from the Jackson Laboratory. Mice were fed a regular diet (10% kcal fat, D12450B, Research Diets) or a high-fat diet (60% kcal fat, D12492, Research Diets) as indicated. For glucose tolerance tests, mice were intraperitoneally (i.p.) injected with 10 mg kg 21 rosiglitazone or MRL24 for 6 days, and fasted overnight before i.p. injection of 2 g kg 21 D-glucose.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
